Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO

被引：0

作者：

Thorsten O. Götze

Pompiliu Piso

Sylvie Lorenzen

Ulli S. Bankstahl

Claudia Pauligk

Moustafa Elshafei

Giuseppe Amato

Daniel Reim

Wolf O. Bechstein

Alfred Königsrainer

Stefan P. Mönig

Beate Rau

Matthias Schwarzbach

Salah-Eddin Al-Batran

机构：

[1] Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest,Department for General and Visceral Surgery

[2] UCT-University Cancer Center,Third Department of Internal Medicine (Hematology/Medical Oncology), Klinikum Rechts der Isar

[3] Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,Department of General Surgery and Emergency

[4] Hospital Barmherzige Brueder,Klinik und Poliklinik für Chirurgie, Klinikum rechts der Isar

[5] University of Regensburg,Department of General and Visceral Surgery

[6] Technische Universitat Munchen,Department of General

[7] Bariatrische und Metabolische Chirurgie,, Visceral Surgery and Transplantation

[8] Krankenhaus Nordwest,Service de Chirurgie viscérale

[9] University of Palermo,Department of Surgery

[10] Technische Universität München,undefined

[11] University Hospital Frankfurt,undefined

[12] University Hospital Tübingen,undefined

[13] Hôpitaux Universitaires de Genève,undefined

[14] Campus Charité Mitte,undefined

[15] Campus Virchow-Klinikum CCM/CVK,undefined

[16] Clinic for General,undefined

[17] Visceral,undefined

[18] Vascular and Thoracic Surgery,undefined

[19] Klinikum Frankfurt Höchst,undefined

来源：

BMC Cancer | / 21卷

关键词：

Gastric cancer; Gastroesophageal junction cancer; Lauren- classification; Signet ring cells; HIPEC; Hyperthermic intraperitoneal chemotherapy; FLOT- regimen; Gastrectomy; Quality of life; Cisplatin; Peritoneal carcinomatosis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 40 条

[1] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"-(FLOT9) trial of the AIO/CAOGI /ACO
Goetze, Thorsten O.
Piso, Pompiliu
Lorenzen, Sylvie
Bankstahl, Ulli S.
Pauligk, Claudia
Elshafei, Moustafa
Amato, Giuseppe
Reim, Daniel
Bechstein, Wolf O.
Koenigsrainer, Alfred
Moenig, Stefan P.
Rau, Beate
Schwarzbach, Matthias
Al-Batran, Salah-Eddin
BMC CANCER, 2021, 21 (01)
[2] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III "PREVENT" trial of the AIO/CAOGI/ACO
Bankstahl, U. S.
Al-Batran, S-E.
Piso, P.
Lorenzen, S.
Ostrzyzek, M.
Pauligk, C.
Habibzade, T.
Schenk, M.
Schlenska-Lange, A.
Reim, D.
Bechstein, W. O.
Koenigsrainer, A.
Moenig, S. P.
Rau, B.
Schwarzbach, M.
Goetze, T. O.
ANNALS OF ONCOLOGY, 2021, 32 : S1075 - S1075
[3] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III "PREVENT" trial of the AIO /CAOGI /ACO.
Goetze, Thorsten Oliver
Piso, Pompiliu
Lorenzen, Sylvie
Bankstahl, Ulli Simone
Ostrzyzek, Marcin
Pauligk, Claudia
Habibzade, Timursah
Reim, Daniel
Bechstein, Wolf Otto
Konigsrainer, Alfred
Monig, Stefan Paul
Rau, Beate
Schwarzbach, Matthias
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO
Goetze, Thorsten
Piso, Pompiliu
Bankstahl, Ulli Simone
Pauligk, Claudia
Volk, Claudia
Knapp, Fabienne
Sookthai, Disorn
Lorenzen, Sylvie
Schenk, Michael
Wiegering, Armin
Jo, Peter
Werner, Jens
Hoelzen, Jens Peter
Stange, Daniel E.
Stein, Alexander
Schmalenberg, Harald
Senkal, Metin
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 359 - 359
[5] Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion-A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
Al-Batran, Salah-Eddin
Hofheinz, Ralf Dieter
Schmalenberg, Harald
Strumberg, Dirk
Goekkurt, Eray
Angermeier, Stefan
Zander, Thomas
Potenberg, Jochem
Kopp, Hans Georg
Pink, Daniel
Siegler, Gabriele Margareta
Schenk, Michael
De Vita, Ferdinando
Maiello, Evaristo
Gaiser, Timo
Sookthai, Disorn
Bankstahl, Ulli Simone
Pauligk, Claudia
Goetze, Thorsten Oliver
Homann, Nils
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK
Al-Batran, S-E.
Pauligk, C.
Hofheinz, R. D.
Lorenzen, S.
Wicki, A.
Siebenhuener, A. R.
Schenk, M.
Thuss-Patience, P. C.
Kretzschmar, A.
Bolling, C.
Eigendorff, E.
Angermeier, S.
Pink, D.
Geissler, M.
Goekkurt, E.
Schmalenberg, H.
Waberer, L.
Talbot, J. J.
Goetze, T. O.
Homann, N.
ANNALS OF ONCOLOGY, 2019, 30 : 324 - 324
[7] Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma- Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM
Al-Batran, S-E.
Hofheinz, R. D.
Schmalenberg, H.
Strumberg, D.
Goekkurt, E.
Angermeier, S.
Zander, T.
Potenberg, J.
Kopp, H-G.
Pink, D.
Siegler, G. M.
Schenk, M.
De Vita, F.
Maiello, E.
Gaiser, T.
Sookthai, D.
Bankstahl, U. S.
Pauligk, C.
Goetze, T. O.
Homann, N.
ANNALS OF ONCOLOGY, 2020, 31 : S901 - S901
[8] Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca A phase II trial of the German AIO.
Hofheinz, Ralf
zur Hausen, Gerrit
Borchert, Kersten
Kretzschmar, Albrecht
Ebert, Matthias Philip
Ettrich, Thomas Jens
Koenigsmann, Michael
Haag, Georg Martin
Hagen, Volker A.
Hoehler, Thomas
Homann, Nils
Kroening, Hendrik
Reichardt, Peter
Rieger, Michael
Teschendorf, Christian
Goekkurt, Eray
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Al-Batran, Salah-Eddin
Pauligk, Claudia
Hofheinz, Ralf
Lorenzen, Sylvie
Wicki, Andreas
Siebenhuener, Alexander Rheinhard
Schenk, Michael
Welslau, Manfred
Heuer, Vera
Goekkurt, Eray
Schmalenberg, Harald
Thuss-Patience, Peter C.
Waberer, Lisa
Talbot, Jonathan
Goetze, Thorsten Oliver
Homann, Nils
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
Goetze, Thorsten Oliver
Hofheinz, Ralf-Dieter
Schmalenberg, Harald
Strumberg, Dirk
Goekkurt, Eray
Angermeier, Stefan
Zander, Thomas
Potenberg, Jochem
Kopp, Hans-Georg
Pink, Daniel
Siegler, Gabriele Margareta
Schenk, Michael
De Vita, Ferdinando
Maiello, Evaristo
Gaiser, Timo
Sookthai, Disorn
Brulin, Tanita
Pauligk, Claudia
Homann, Nils
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 →